June 2024 – Page 15

Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments

1 year ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, Congress (U.S. Legislature), Delta - greek letter, EASL, Hepatitis, Single Agent Therapy, Vir Biotechnology

Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress

Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet

1 year ago talkbio0Tagged Alphabet, Ashkenazi, Biopharma, CFO, Eli, Eli Lilly, Google, Pichai, Ruth, Science of Anatomy, Tech Industry

Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry

Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation

1 year ago talkbio0Tagged Aaron Berg, Amarin, CEO, Holt, Leadership, Patrick, resignation, Transition Mutation

Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition

Moderna and Merck’s Cancer Vaccine Shows Promising Results in Combination with Keytruda

1 year ago talkbio0Tagged ASCO, Beginning, Cancer Vaccines, Keytruda, melanoma, Merck, Moderna, pilot program, RNA, Messenger, United States Food and Drug Administration

Moderna, Merck, Cancer Vaccine, Keytruda, Melanoma, mRNA Technology, ASCO, FDA, Rare Disease, START Pilot Program

Sanofi’s Sarclisa Achieves First-in-Class Win, Poised to Surpass J&J in Multiple Myeloma Treatment

1 year ago talkbio0Tagged anti-CD38 therapy, ASCO, IMROZ Study, J&J, Multiple Myeloma, sanofi, Sarclisa, VRd

Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients

ConcertAI Partners with NVIDIA, Unveils Advanced AI Tools for Oncology Research and Treatment

1 year ago talkbio0Tagged AI, Artificial Intelligence, Cara, clinical simulations, Clinical Trials, ConcertAI, Multi-Modal Oncology Data, NVIDIA, oncology research, outcomes

ConcertAI, NVIDIA, AI tools, oncology research, clinical simulations, CARA AI platform, multi-modal oncology data, clinical trials, patient outcomes

Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision

1 year ago talkbio0Tagged Biliary Tract Cancer, Decision, erbB-2 Receptor, Jazz, Priority Review, United States Food and Drug Administration, Zanidatamab

Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review

GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment

1 year ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, Blenrep, CAR-T, Darzalex, DREAMM-7, DREAMM-8, Multiple Myeloma, Pomalyst, SmithKline Beecham, Velcade

Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate

RYBREVANT: A Breakthrough in Lung Cancer Treatment

1 year ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

1 year ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials